332013-43-1 Usage
General Description
(2-Methylaminocarbonyl-4-pyridyl)methanol is a chemical compound that consists of a pyridine ring with a methylamino carbonyl group and a hydroxymethyl group attached to it. It is often used as a building block in the synthesis of pharmaceuticals and other organic compounds. The compound has potential applications in the pharmaceutical industry due to its ability to act as a versatile intermediate in the production of various drugs and biologically active molecules. Additionally, it can also be used as a reagent in organic synthesis and a precursor in the preparation of other chemical compounds. However, it is important to handle this chemical with caution and follow proper safety protocols, as it may pose health hazards if mishandled.
Check Digit Verification of cas no
The CAS Registry Mumber 332013-43-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,2,0,1 and 3 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 332013-43:
(8*3)+(7*3)+(6*2)+(5*0)+(4*1)+(3*3)+(2*4)+(1*3)=81
81 % 10 = 1
So 332013-43-1 is a valid CAS Registry Number.
332013-43-1Relevant articles and documents
Design, synthesis and biological evaluation of indole derivatives as novel inhibitors targeting B-Raf kinase
Wu, Zeng,Yan, Ming,Hu, Shi-He,Yu, Zhi-Cheng,Zhu, Yong,Cheng, Ya-Dong,Liu, Hai-Chun,Zhang, Yan-Min,Yao, Si-Hui,Tang, Wei-Fang,Lu, Tao
, p. 351 - 354 (2014/02/14)
A series of novel indole derivatives were designed and synthesized and their inhibitory activity against B-Raf and HepG2 cell were also described. Among them, compounds 7a and 7b exhibited excellent potency, which showed the potential for further research
COMPOUNDS FOR TREATING PULMONARY HYPERTENSION
-
, (2008/06/13)
The present invention relates to pharmaceutical compositions and combinations for treating, preventing or managing pulmonary hypertension comprising small molecule heterocyclic pharmaceuticals, and more particularly, substituted pyridines and pyridazines optionally combined with at least one additional therapeutic agent.
